IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Among the resulting drugs, DT388IL-3 has shown some promise in clinical trials [19], [20], whereas the DT389-IL-2 recombinant toxin (DAB389-IL-2, denileukin diftitox-Ontak) has been approved by the FDA for clinical use in advanced stage cutaneous T-cell lymphoma (reviewed in [21]–[23].